FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD)
Artelo Biosciences is a biopharmaceutical company dedicated to applying true biopharma discipline in leveraging past research and leading-edge, world-class science to accelerate the development and commercialization of a diverse portfolio of novel, endocannabinoid system modulating therapeutics. Our programs have the potential to dramatically improve patient care in major markets. With our headquarters team in San Diego, California, USA and our European offices in Dublin, Ireland, and Alderley Park, Cheshire, UK, Artelo established a presence in key global biopharma innovation hubs with close access to world-class research expertise. Artelo’s research and development leverages the skill, knowledge and experience of our collaboration partners in Europe and North America.
The ICRS is a non-political, non-religious organization dedicated to scientific research in all fields of the cannabinoids, ranging from biochemical, chemical and physiological studies of the endogenous cannabinoid system to studies of the abuse potential of recreational Cannabis.
In addition to acting as a source for impartial information on Cannabis and the cannabinoids, the main role of the ICRS is to provide an open forum for researchers to meet and discuss their research.
Membership – The International Cannabinoid Research Society is a scientific association with more than 500 international Members, all active researchers in the field of endogenous, plant-derived and synthetic cannabinoids and related bioactive lipids.
COMMITMENT TO PROVIDING THE MOST EFFICIENT, SAFE AND CLEAN PRODUCT IN THE WORLD.
Can Pharmaceuticals Group Ltd., with the “better” brand (BET), is a company that develops cannabis plant-based drugs and therapies that have been developed and developed according to the needs of clients, therapists and various medical professionals.
Our vision is to ensure medical treatment based on a cannabis plant that is free of chemicals, consistent and stable, to meet every patient in debilitating medical conditions, anywhere in the world to the highest standards.
קבוצת קאן פרמצבטיקה בע”מ בעלת המותג “better” (בטר) הינה חברה המפתחת תרופות וטיפולים מבוססי צמח הקנאביס שהושבחו ופותחו בהתאם לצרכי הלקוחות, הרופאים המטפלים וההתויות השונות.
החזון שלנו הוא להבטיח טיפול רפואי המבוסס על צמח הקנאביס נקי מכימיקלים, עקבי ויציב, שייתן מענה לכל מטופל במצב רפואי מתיש, בכל
The Greenwich Biosciences mission is rooted in unlocking the potential of cannabinoid medicines to address serious medical conditions with limited treatment options.